TLDR
- Tenet Healthcare stock jumped 23% after posting Q2 adjusted EPS of $6.12, crushing the $4.26 analyst estimate
- Tenet raised its full-year EPS guidance to $20.30–$21.69, up from $16.38–$18.68
- HCA Healthcare rose a more modest 3.7% after reiterating pre-announced Q2 results
- HCA cut its full-year EPS outlook to $28.70–$30.50, down from $29.10–$31.50
- Barclays raised its Tenet price target to $271 from $240, maintaining an Overweight rating
Tenet Healthcare (THC) stock surged 23% on Friday, putting it on pace for its biggest single-day gain since February. The move came after the company posted Q2 results that blew past Wall Street expectations and sharply lifted its full-year outlook.
Tenet Healthcare Corporation, THC
Tenet reported Q2 adjusted earnings of $6.12 per share, well ahead of the $4.26 analysts had forecast. Operating revenue rose 6.8% to $5.63 billion, topping the expected $5.43 billion.
The company also raised its full-year adjusted EPS guidance to a range of $20.30 to $21.69, up from the prior range of $16.38 to $18.68. Full-year net operating revenue guidance was lifted to $21.9 billion–$22.5 billion, versus the previous $21.5 billion–$22.3 billion.
$THC Q2 2026 earnings: Massive Margin Expansion and Buybacks Eclipse Volume Softness
Tenet Healthcare delivered a dramatic Q2 beat, fueled by exceptional hospital margin expansion and pricing power in its ambulatory segment. While net operating revenues grew a respectable 6.8%… pic.twitter.com/pxCFX3irFc
— Finsee (@Finsee_main) July 24, 2026
At the midpoint of each new range, both figures come in well ahead of what analysts had been expecting — $17.94 per share and $21.97 billion in revenue.
HCA Healthcare Tells a Different Story
HCA Healthcare also reported Friday, but the reaction was far more muted. HCA rose 3.7%, compared to Tenet’s double-digit surge.
Much of that gap comes down to timing. HCA pre-announced its Q2 results on July 14, meaning Friday’s official report held few surprises for investors.
HCA posted Q2 adjusted EPS of $7.59, just above the $7.56 expected. Revenue climbed 9% to $20.23 billion, topping the $19.76 billion consensus.
However, a $400 million net benefit from Medicaid supplemental payments did a lot of the work. Excluding that, results were more complicated.
HCA noted a rise in uninsured patients, partly due to more people losing exchange-based coverage during the quarter. The company estimates that shift cost it roughly $400 million in pre-tax income.
HCA Cuts Full-Year Guidance
HCA lowered its full-year EPS guidance to $28.70–$30.50, down from a prior range of $29.10–$31.50. The company also tightened its revenue outlook to $77 billion–$79.5 billion, compared with $76.5 billion–$80 billion previously.
The S&P 500 dipped slightly on Friday, making Tenet’s 23% gain stand out even more against the broader market backdrop.
Barclays responded by raising its price target on Tenet to $271 from $240, keeping an Overweight rating. The firm said Tenet’s Q2 performance “stands out and reinforces the case for a premium valuation,” particularly given guidance cuts from other hospital operators.
Tenet’s ambulatory surgery center network has been a key differentiator. While both companies run hospitals and outpatient facilities across the U.S., Tenet leans more heavily on its surgery center business, which has been a consistent driver of margin performance.
Barclays’ updated $271 price target represents further upside from Friday’s elevated levels following the post-earnings move.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
